The short answer
Yohimbe products can cause blood-pressure and stimulant-type adverse effects, but the added risk from taking them with oral phenylephrine has not been quantified in the sources checked. Have a pharmacist or clinician review this combination before use, especially if you have high blood pressure or heart disease.
What this answer covers
Oral phenylephrine hydrochloride with yohimbe bark supplements, represented in the dataset as Pausinystalia johimbe. Sources commonly use Pausinystalia yohimbe. Purified yohimbine studies are indirect; injected phenylephrine experiments do not establish oral supplement interactions.
- Supplement or preparation
- Pausinystalia johimbe
- Medication ingredient
- phenylephrine
Is yohimbe the same as yohimbine?
Yohimbine is one compound in yohimbe bark. Supplements may contain very different amounts, and some do not state that amount reliably. Results from a measured dose of purified yohimbine therefore cannot be applied directly to every bark extract or multi-ingredient sexual-performance product.
What human evidence supports caution?
In a study using 10 mg oral yohimbine, diastolic pressure rose significantly in people with untreated hypertension, but not in healthy participants. A poison-control review also recorded rapid heartbeat, anxiety and hypertension after yohimbine-containing products. Neither study measured the effect of adding oral phenylephrine.
Does the evidence show how likely harm is?
No. Poison-control reports describe people who were already symptomatic and do not give the risk among all users. The purified-yohimbine trial used a different exposure from an unknown-strength bark supplement. These limitations prevent a reliable numerical risk estimate for the combination.
What should be reviewed before use?
Bring the full supplement and medicine labels, including any caffeine or other stimulants. High blood pressure or heart disease can already rule out some phenylephrine cold medicines. A reassuring phenylephrine-only trial excluded herbs, so it cannot establish that this combination is safe, and no protective spacing interval was identified.
Evidence and practical considerations
Side effects & toxicity
Yohimbe-associated adverse reports and oral purified-yohimbine effects support caution, but do not establish increased stimulant toxicity for the exact oral phenylephrine/bark pair. Product composition and hypertension materially affect interpretation.
- Exact scope
- Oral phenylephrine hydrochloride with yohimbe bark supplements, represented in the dataset as Pausinystalia johimbe. Sources commonly use Pausinystalia yohimbe. Purified yohimbine studies are indirect; injected phenylephrine experiments do not establish oral supplement interactions. with oral phenylephrine hydrochloride supplying the exact phenylephrine active moiety, RxCUI 8163
- Medication form and route
- oral
- Timing or duration
- During co-use; source-specific durations are retained without inferring a universal safe duration.
What remains uncertain
- No controlled oral bark/phenylephrine co-use trial located. Poison-control cases are selected symptomatic reports; purified alkaloid findings do not quantify variable bark products.
Factors that may matter: yohimbine content and product accuracy; hypertension; additional stimulant ingredients; oral versus injected phenylephrine.
Read the supporting source summaries
Source 1: regulatory product information
medicines.org.uk · Source check Sep 10, 2026
Population: People using this oral cold and flu combination product, age 16 years and older.
The product combines phenylephrine and caffeine, warns against excessive additional caffeine, and lists hypertension and heart disease among contraindications. Caffeine and phenylephrine adverse effects include palpitations and sleep-related symptoms.
How this applies: Exact phenylephrine active moiety and caffeine co-formulation. Botanical applicability is an inference only when the supplement actually supplies caffeine; other herb constituents and other phenylephrine routes are not evaluated.
Instructions apply to this finished oral product. They neither establish a universal caffeine threshold or spacing interval nor prove safety of isolated phenylephrine with supplements. Other ingredients confound extrapolation.
Source 2: government botanical evidence summary
nccih.nih.gov · Source check Sep 10, 2026
Population: People using yohimbe supplements.
Yohimbine-associated blood-pressure problems and serious adverse events are described. Product labels often do not reliably state yohimbine content, and supplements differ from prescription yohimbine.
How this applies: Supports the distinction between bark and purified yohimbine and the need to assess the specific product; does not establish the amount of additional risk with phenylephrine.
No exact oral phenylephrine interaction quantified. Botanical node spelling johimbe is retained, while source uses yohimbe.
Source 3: randomized placebo crossover pharmacology study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Twenty-five healthy volunteers and twenty-nine untreated hypertensive patients.
Diastolic pressure increased significantly only in participants with hypertension. Norepinephrine increased in both groups.
How this applies: Indirect constituent evidence for a potential blood-pressure concern, with contrary healthy-participant findings retained.
Purified yohimbine, not a characterized yohimbe bark supplement; no phenylephrine. Results are not uniform across populations.
Source 4: retrospective poison-control case review
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 238 symptomatic adult exposure reports from 2000-2006.
Reported events included tachycardia, anxiety or agitation, gastrointestinal symptoms and hypertension.
How this applies: Real-world botanical safety signal without proof of exact pair synergy or incidence.
Selected symptomatic reports with no denominator of all users; heterogeneous products and uncertain doses. Abstract does not identify a phenylephrine co-use subgroup.
Source 5: randomized placebo-controlled crossover study
pmc.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Twenty-eight healthy normotensive adults.
Cardiovascular tolerability was broadly comparable with placebo. Exposure increased more than proportionally with dose; individual concentrations varied substantially.
How this applies: Medication-only evidence prevents presenting every oral phenylephrine dose as inevitably raising blood pressure. It does not show that any supplement combination is safe.
Selected healthy participants, single doses, no supplement co-use. The authors state the design does not adequately assess proarrhythmic risk. Sponsor funded the study and authors were sponsor employees.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Changed the broad stimulant-interaction claim to an unconfirmed oral pair with explicit independent safety evidence. Added botanical/alkaloid identity, hypertension subgroup and poison-report denominator limitations. | |
| Research summary published |
Article revision: e2e52a0f9f3b8444
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.